Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1801]

Bladder cancer updates from the second half of 2024

Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos

Bladder cancer updates from the second half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos )

30 minute infusion of isatuximab shows potential in newly diagnosed multiple...

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz

EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

CDK4/6 inhibitors and endocrine therapy in elderly female patients with...

Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC ( Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Dr Prashant Mehta - Amrita Hospital, Karala, India

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients ( Dr Prashant Mehta - Amrita Hospital, Karala, India )

Advancements in head and neck cancer treatment in India

Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India

Advancements in head and neck cancer treatment in India ( Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India )

Multiple Myeloma: evolving paradigm - Panel Discussion

Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr...

Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy...

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

More from ecancer